Ovarian Cancer: Efficacy and Safety Study of Cediranib in Combination With Olaparib
in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)
How effective and tolerable is treatment with the combination of cediranib and olaparib
in patients with ovarian cancer?
Basic Study Information
Purpose:Location: cancer center
The purpose of the study is to see if the combination of two drugs, cediranib and
olaparib, is effective and tolerable in patients with ovarian cancer who have received
at least 3 prior chemotherapy treatments, including treatment that included either
carboplatin or cisplatin, and their disease came back within 6 months of the last
dose of chemotherapy that included either cisplatin or carboplatin.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02889900?term=D8488C00001&rank=1
Study Reference #: IGYO-16111
Lead Researcher (Principal Investigator)
Lead Researcher: Richard Moore
Study Contact InformationStudy Coordinator: Laura Mitchell
Phone: (585) 275-7763
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search